跳至主要内容
临床试验/NCT06631417
NCT06631417已完成1 期

A Trial to Investigate Relative Bioavailability of Three Different BI 1291583 Formulations Following Oral Administration at Two Dose Levels to Healthy Subjects (an Open-label, Randomised, Single-dose, Three-period Crossover Trial Consisting of 2 Parts)

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年10月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz)

研究概览

简要总结

The main objective of this trial is to investigate the relative bioavailability of two different formulations of BI 1291583 (test formulations) compared to BI 1291583 reference formulation administered at two different dose levels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

BI 1291583 formulation 1 then formulation 2 then formulation 3 (part A)

Experimental

干预措施: BI 1291583 (Drug)

BI 1291583 formulation 1 then formulation 2 then formulation 3 (part B)

Experimental

干预措施: BI 1291583 (Drug)

结局指标

主要结局

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz)

时间窗: Up to 22 days

Maximum measured concentration of the analyte in plasma (Cmax)

时间窗: Up to 22 days

次要结局

  • Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞)(Up to 22 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验